RELIEF THERAPEUTICS Holding ROE 2024

Čo robí RELIEF THERAPEUTICS Holding?

RELIEF THERAPEUTICS Holding SA is a Swiss biotech company that specializes in the research and development of novel therapies for the treatment of serious diseases. The company was founded in 2016 and is based in Geneva. The history of RELIEF THERAPEUTICS began with the discovery of a promising molecule called Aviptadil. Aviptadil is a synthetic peptide derived from the natural hormone VIP (Vasoactive Intestinal Peptide). It has the ability to regulate a variety of biological processes in the body and has shown promise as a therapy for a range of diseases. Since its inception, the company has formed a number of partnerships and collaborations with other companies and research institutions to support its research projects and bring its technology to market. The business model of RELIEF THERAPEUTICS is based on the research and development of innovative therapies for a variety of serious diseases for which there is currently no effective treatment. The company focuses on the research and development of peptides and proteins as a new class of therapeutic agents. RELIEF THERAPEUTICS has several business segments active in drug development. The first segment is the respiratory diseases segment, in which the company utilizes its core expertise in the development of Aviptadil to explore innovative therapies for severe respiratory diseases such as idiopathic pulmonary fibrosis (IPF), acute and chronic respiratory distress syndromes (ARDS/CRDS), and asthma. Another important segment of RELIEF THERAPEUTICS is cancer research. The company is working on the development of new cancer therapies based on Aviptadil, targeting the regulation of tumor growth and metastasis formation. The third segment of the company is pain therapy. Here, RELIEF THERAPEUTICS is working on the development of peptide-based analgesics to alleviate pain in various conditions such as cancer, neuropathic pain, and postoperative pain. RELIEF THERAPEUTICS currently offers several products based on Aviptadil. One of these products is RLF-100, also known as ZYESAMI, a potential drug for the treatment of severe respiratory diseases such as ARDS/CRDS and COVID-19. RLF-100 is an inhalable Aviptadil specifically developed for the treatment of respiratory diseases and has shown high efficacy in clinical studies. Another product from RELIEF THERAPEUTICS is RLF-888, a potential drug for the treatment of neuropathic pain. RLF-888 has been developed as a peptide-based analgesic and has shown promising results in preclinical studies. In 2021, RELIEF THERAPEUTICS acquired a majority stake in APR Applied Pharma Research SA, expanding its product range and business areas. APR is increasingly gaining importance in the acute aplastic pain market and could prove to be an important part of RELIEF THERAPEUTICS' product diversity in the future. Overall, RELIEF THERAPEUTICS has positioned itself as a promising player in the biotech industry and continues to strive to develop innovative therapies for serious diseases to help patients worldwide. RELIEF THERAPEUTICS Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.